DataVXACS NanoPaper
journal article·2018-11-27

Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics

Betina Børresen, Jonas R. Henriksen, Gael Clergeaud, Jennifer S. Jørgensen, Fredrik Melander, Dennis R. Elema, Janos Szebeni, Svend Aage Engelholm, Annemarie T. Kristensen, Andreas Kjær, Thomas L. Andresen, Anders E. Hansen

ACS Nano· Volume 12· Issue 11
Publisher page
Source abstract

Abstract

Cu-liposome injection, ABC could be prevented. Importantly, signs of liposome tracer breakdown with subsequent renal excretion were observed. These findings highlight the importance of the ABC phenomenon for liposomal predictive imaging in a clinically relevant setting and show that carefully planned application is central to avoid potential detrimental effects on patient benefit.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Radiopharmaceutical Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1870 Frederiksberg C, Denmark

DTU Nanotech, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark

DTU Nutech, Center for Nuclear Technologies, Technical University of Denmark, 4000 Roskilde, Denmark

Nanomedicine Research and Education Center, Semmelweis University, Budapest 1085, Hungary

Department of Radiotherapy, Copenhagen University Hospital, 2100 Copenhagen Ø, Denmark

Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, 2100 Copenhagen Ø, Denmark and Cluster for Molecular Imaging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark

Funding

Strategiske Forskningsr?d · Region Hovedstaden · Rigshospitalet · FP7 Ideas: European Research Council · Lundbeckfonden · Innovationsfonden · Novo Nordisk Fonden

References (40)

Show source-provided references
1. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
2. 10.1016/j.jconrel.2014.03.05710.1016/j.jconrel.2014.03.057 ↗
3. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
4. 10.1021/acsnano.5b0132410.1021/acsnano.5b01324 ↗
5. 10.1093/jjco/hyp07410.1093/jjco/hyp074 ↗
6. 10.1038/nnano.2012.4510.1038/nnano.2012.45 ↗
7. 10.1096/fj.07-9150com10.1096/fj.07-9150com ↗
8. 10.1111/j.1349-7006.2009.01323.x10.1111/j.1349-7006.2009.01323.x ↗
9. 10.1002/1097-0142(197209)30:3<639::AID-CNCR2820300308>3.0.CO;2-310.1002/1097-0142(197209)30:3<639::AID-CNCR2820300308>3.0.CO;2-3 ↗
10. Znati C. A. · Clin. Cancer Res. · 2003 · 9 · 5508
11. Krishnan E. C. · J. Natl. Cancer Inst. · 1987 · 79 · 132110.1093/jnci/79.6.1321 ↗
12. 10.1016/0360-3016(88)90359-810.1016/0360-3016(88)90359-8 ↗
13. 10.3389/fonc.2012.0016510.3389/fonc.2012.00165 ↗
14. 10.1667/RR2773.110.1667/RR2773.1 ↗
15. 10.1016/j.nano.2017.08.01310.1016/j.nano.2017.08.013 ↗
16. 10.1016/j.jconrel.2013.07.02610.1016/j.jconrel.2013.07.026 ↗
17. 10.1016/j.ijpharm.2012.07.04910.1016/j.ijpharm.2012.07.049 ↗
18. 10.1016/j.ejps.2011.11.01410.1016/j.ejps.2011.11.014 ↗
19. 10.3390/pharmaceutics301000110.3390/pharmaceutics3010001 ↗
20. 10.1016/j.jconrel.2005.04.00310.1016/j.jconrel.2005.04.003 ↗
21. 10.1016/j.jconrel.2012.02.02910.1016/j.jconrel.2012.02.029 ↗
22. Laverman P. · J. Pharmacol. Exp. Ther. · 2001 · 298 · 60710.1016/S0022-3565(24)29419-2 ↗
23. 10.1007/s11095-012-0934-y10.1007/s11095-012-0934-y ↗
24. 10.1016/j.jconrel.2006.08.01710.1016/j.jconrel.2006.08.017 ↗
25. 10.1016/j.ijpharm.2014.09.04710.1016/j.ijpharm.2014.09.047 ↗
26. 10.1016/j.jconrel.2006.01.00510.1016/j.jconrel.2006.01.005 ↗
27. 10.1021/acs.molpharmaceut.5b0014410.1021/acs.molpharmaceut.5b00144 ↗
28. 10.1016/j.jconrel.2007.02.01010.1016/j.jconrel.2007.02.010 ↗
29. Dams E. T. · J. Pharmacol. Exp. Ther. · 2000 · 292 · 107110.1016/S0022-3565(24)35391-1 ↗
30. 10.1016/j.ijpharm.2013.01.01210.1016/j.ijpharm.2013.01.012 ↗
31. 10.1002/jps.2325410.1002/jps.23254 ↗
32. 10.1016/j.jconrel.2007.11.00910.1016/j.jconrel.2007.11.009 ↗
33. 10.1248/bpb.b14-0065310.1248/bpb.b14-00653 ↗
34. 10.2147/IJN.S4170110.2147/IJN.S41701 ↗
35. 10.1039/C5NR03626G10.1039/C5NR03626G ↗
36. 10.1081/LPR-12000479010.1081/LPR-120004790 ↗
37. 10.1177/107815520708011710.1177/1078155207080117 ↗
38. 10.1684/ejd.2017.298610.1684/ejd.2017.2986 ↗
39. 10.1021/acsami.5b0461210.1021/acsami.5b04612 ↗
40. Mayer L. D. · J. Pharmacol. Exp. Ther. · 1997 · 280 · 140610.1016/S0022-3565(24)36522-X ↗